Oxford Nanopore Technologies PLC

Oxford Nanopore Technologies’ share dip and negative P/E reveal biotech’s profit‑risk tension, prompting investors to weigh breakthrough tech against shaky earnings.

Oxford Nanopore names Francis Van Parys CEO, aiming to turbo‑charge its nanopore sequencing business and expand clinical, pharma, and defense markets.

Oxford Nanopore Technologies PLC reported a stronger-than-expected financial performance for the first half of the year, but its shares declined in value, highlighting the complex dynamics at play in the financial markets.

Oxford Nanopore Technologies PLC has reported a strong first-half performance in 2025, with a 28% revenue growth and a reaffirmed full-year outlook, solidifying its position as a leader in molecular detection and analysis.

Oxford Nanopore Technologies PLC has received a ‘buy’ recommendation from Investec, setting a price target of 200 pence, as the company continues to innovate in the health care sector.